文章发表Publication |
1. Zan GY, Wang Q, Wang YJ, Chen JC, Wu X, Yang CH, Li M, Liu Y, Hu XW, Shu XH*, Liu JG*. p38 mitogen-activated protein kinase activation in amygdala mediatesκopioidreceptor agonist U50,488H-induced conditioned place aversion. Neuroscience. 2016;320:122-8. 2.Shu XH, Wang LL, Li H, Song X, Shi S, Gu JY, Wu ML, Chen XY, Kong QY, LiuJ.Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications. Neurotherapeutics. 2015;12(2):491-501. 3.Shu XH, Keller TC 4th, Begandt D, Butcher JT, Biwer L, Keller AS, Columbus L,Isakson BE. Endothelial nitric oxide synthase in the microcirculation. Cell Mol Life Sci. 2015;72(23):4561-75. 4. Hu Y, Li S, Liu F, Geng L,Shu XH*, Zhang J*. Discovery of novel nonpeptideallosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays. Bioorg Med Chem Lett. 2015;25(19):4069-73. 5.Shu XH, Sun XX, Li H, Song X, Wang LL, Shi S, Liu J. Resveratrol inducesapoptosis of medulloblastoma cells without affecting astrocytes and neurons. Pediatr Blood Cancer. 2014;61(s2):339-40. 6. Hu Y, Li C, Li H, Li M,Shu XH*. Resveratrol-mediated reversal of tumormulti-drug resistance. Curr Drug Metab. 2014;15(7):703-10. 7. Shu XH, Li H, Sun XX, Sun Z, Wu ML, Kong QY, Liu J. Bioactive form ofresveratrol in glioblastoma cells and its safety for normal brain cells. Functional Foods in Health and Disease. 2013;3:146-53. 8.杨阳,李传刚,舒晓宏*.白藜芦醇代谢模式的研究进展.中国药学杂志.2013;48:2081-3 9.Shu XH, Li H, Sun XX, Wang Q, Wu ML, Kong QY, Liu J. Metabolic patterns andbiotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS One. 2011;6:e27484. 10.Shu XH,Li H, Sun Z, Wu ML, Ma JX, Wang JM, Wang Q, Sun Y, Fu YS, Chen XY,Kong QY, Liu J. Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol. 2010;79(10):1516-25 |
